Price as of close on Nov 3, 2026 · Financials updated Oct 6, 2026
Basics
Sector
Healthcare
Industry
Health Information Services
Country
United States
Market cap
1.7B USD
Enterprise value
1.5B USD
Full-time employees
1,515
Overall health
Drawback:less profitable than most peersless profitable than peers
Drawback:growing more slowly than most peersgrowing more slowly than peers
Drawback:higher risk than most peers: its share price swings more than most peers’ (beta 1.43 vs a peer median of 0.63)higher risk: bigger price swings (beta 1.43 vs peers 0.63)
About average: valuation
Ranks #903 of 1,157 healthcare companies (bottom 23%)
Earnings slid into a loss. Loss per share this year after a profit last year.
Certara made a loss per share in its latest year after a profit the year before.
Valuation signals disagree.Cheaper than 53% of peers on operating cash profit (EBITDA), but only 0% on earnings.Cheaper than 53% of peers on operating cash profit, but only 0% on earnings.
Relative to its operating cash profit (EBITDA), Certara looks cheaper than 53% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its operating cash profit, Certara looks cheaper than 53% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Sales growing faster than profits. Since 2022: revenue +25%, operating profit −35%.
Since 2022, Certara's revenue changed +25% while operating profit fell 35%: costs rose faster than sales.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Certara reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Sector-normalized EBITDA, earnings, and free cash flow yields.
Earnings yield-4.1%
SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148
EBITDA yield4.5%
SEC filings · 12 months to Jun 2026Reported value50% base weight · Z-score 0.11Sector median: 0.0401 · MAD: 0.0401
Free cash flow yield4.8%
SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Certara
Is Certara getting weaker?
Its latest SEC filing (Aug 4, 2026) showed no major changes. Its overall score is unchanged at 35/100 since Oct 28, 2026.
How is Certara valued vs its peers?
Priced about in line with its peers. Valuation scores 43/100 against 1,393 healthcare peers.Earnings yield -4.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -4.1% vs peers 1.5% (weaker than 100% of peers).
Is Certara growing?
More slowly than most of its peers. Growth scores 34/100 against 1,393 healthcare peers.Revenue growth 11.1% vs a peer median of 6.1% (stronger than 64% of peers).Revenue growth 11.1% vs peers 6.1% (stronger than 64% of peers).
How profitable is Certara?
Less profitable than most of its peers. Profitability scores 35/100 against 1,393 healthcare peers.Return on assets -4.9% vs a peer median of 1.7% (weaker than 70% of peers).Return on assets -4.9% vs peers 1.7% (weaker than 70% of peers).
How risky is Certara?
Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Beta 1.43 vs a peer median of 0.63 (weaker than 86% of peers).Beta 1.43 vs peers 0.63 (weaker than 86% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jun 30, 2026 · filed Aug 4, 2026 · compared with the quarter ended Mar 31, 2026
No major changes
Previous quarter
Latest quarter
Change
Revenue (12 months)
419.7M USD
421.7M USD
+0.5%
Net income (12 months)
−15.1M USD
−68.4M USD
+353.0%
Operating margin
2.2%
0.6%
−1.6 pts
Free cash flow (12 months)
88.9M USD
80.4M USD
−9.6%
Debt
292.5M USD
291.8M USD
−0.2%
Cash
149.5M USD
184.1M USD
+23.2%
Shares outstanding
155.6M
152.5M
−1.9%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Health Information Services companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2021
FY 2022
FY 2023
FY 2024
FY 2025
Change
Gross margin
61.0%
60.5%
60.2%
—
—
—
Operating margin
4.7%
9.7%
-11.5%
-0.4%
5.0%
▲ 5.5 pts
Net margin
-4.6%
4.4%
-15.6%
-3.1%
-0.4%
▲ 2.7 pts
Return on assets (ROA)
-0.9%
0.9%
-3.5%
-0.8%
-0.1%
▲ 0.7 pts
Return on equity (ROE)
-1.3%
1.4%
-5.3%
-1.1%
-0.2%
▲ 1.0 pts
Free cash flow margin
20.7%
27.1%
22.9%
20.5%
22.6%
▲ 2.1 pts
Current ratio
2.98×
3.32×
2.62×
2.13×
2.05×
▼ 3.4%
Debt to equity
0.28×
0.27×
0.28×
0.28×
0.28×
▼ 1.2%
Interest coverage
0.81×
1.83×
-1.78×
-0.08×
1.06×
▲ >999%
CERT price history
Price history is added with the daily price update and will appear after the next one.